Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 4:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 423 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Acne Vulgaris (Disorder) Clear all
Terminated Not applicable Interventional Accepts healthy volunteers

Restylane Silk Acne Scar Efficacy Evaluation Study

NCT02955381
View directory record Official record
Conditions
Acne, Acne Scars, AdverseEvent
Interventions
Restylane Silk, 1.0 ml, Saline, 1.0 ml
Device
Lead sponsor
Schweiger Dermatology, PLLC
Industry
Eligibility
22 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 10, 2019 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 3 Interventional

DMT310-009 Topical in the Treatment of Acne Vulgaris

NCT06090721
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DMT310, Placebo
Drug
Lead sponsor
Dermata Therapeutics
Industry
Eligibility
9 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
2
States / cities
Freemont, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 22, 2025 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Topical Administration of FMX101 in the Treatment of Moderate-to-Severe Acne Vulgaris

NCT03271021
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX101, Vehicle Foam
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
9 Years and older
Enrollment
1,488 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
98
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 83 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2022 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study Evaluating the Efficacy and Safety of Omnilux Clear on Mitigating Mild to Moderate Acne

NCT06936332
View directory record Official record
Conditions
Acne
Interventions
Omnilux Clear Light Emitting Diode Treatment
Device
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
14 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Use of Oracea and Epiduo Forte in Severe Acne Patients

NCT03457636
View directory record Official record
Conditions
Acne
Interventions
Doxycycline Anhydrous 40 MG, Adapalene/Benzoyl Peroxide Gel 0.3-2.5%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
12 Years and older
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 3, 2019 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers.

NCT01119651
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Tazarotene (Patch application in Challenge Phase)
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated Jun 14, 2017 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Results available

A Study Comparing Two Topicals in the Treatment of Acne Vulgaris

NCT03743038
View directory record Official record
Conditions
Acne Vulgaris
Interventions
FMX101 vehicle, Hydro-alcohol solution
Drug · Other
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa

NCT04179175
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
secukinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
29
States / cities
Rogers, Arkansas • San Diego, California • Whittier, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Comparative Antimicrobial Efficacy of Two Topical Acne Therapies for the Treatment of Facial Acne

NCT00841776
View directory record Official record
Conditions
Acne
Interventions
Duac, Ziana gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Louisville, Kentucky • Mason, Ohio
Source: ClinicalTrials.gov public record
Updated May 25, 2017 · Synced Oct 2, 2026, 4:50 AM EDT
Withdrawn Not applicable Interventional

Topical 5-ALA-PDT With Blu-U Therapy Versus Topical 5-ALA With Pulse Dye Laser In Treating Recalcitrant Acne Vulgaris

NCT00814918
View directory record Official record
Conditions
Acne Vulgaris
Interventions
5-ALA with Blu-U Light, 5-ALA with Candela V-beam Pulse Dye Laser
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 4, 2014 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Not applicable Interventional Results available

Feasibility Study To Collect Safety And Preliminary Efficacy Data For A Radiofrequency Microneedling Device

NCT05254210
View directory record Official record
Conditions
Wrinkles, Fine Lines, Crepey Skin, Acne Scars, Active Acne, Enlarged Pores, Loose Skin
Interventions
RF Device (Potenza™)
Device
Lead sponsor
Cynosure, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Hollywood, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Blue Light Therapy of C. Acnes

NCT04300010
View directory record Official record
Conditions
Acne
Interventions
5% Topical Benzoyl Peroxide Gel, Blue Light Therapy
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 10, 2022 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Double-Blind Efficacy and Safety of CD5789 (Trifarotene) 50µg/g Cream Versus Vehicle Cream in Acne Vulgaris

NCT02556788
View directory record Official record
Conditions
Acne Vulgaris
Interventions
CD5789 (trifarotene) 50µg/g Cream, Placebo Cream
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
9 Years and older
Enrollment
1,212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

A Safety and Efficacy Evaluation of Topical Treatments for Moderate-Severe Facial Acne Vulgaris

NCT02604680
View directory record Official record
Conditions
Acne Vulgaris
Interventions
BLI1100-1, BLI1100-2, BLI1100-3, BLI1100-4, Placebo
Drug
Lead sponsor
Braintree Laboratories
Industry
Eligibility
12 Years to 45 Years
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
50
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2017 · Synced Oct 2, 2026, 4:50 AM EDT
Withdrawn Phase 4 Interventional

A Trial of Pulse Dyed Laser (Chromogenex Regenlite Transform) in the Treatment of Inflammatory Acne Vulgaris

NCT02647528
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Chromogenix Regenlite Transform Treatment, Chromogenix Regenlite Transform Placebo
Device
Lead sponsor
Sadick Research Group
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 6, 2016 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Assessing Local Cutaneous Effects of SB204

NCT02250430
View directory record Official record
Conditions
Acne Vulgaris
Interventions
SB204
Drug
Lead sponsor
Novan, Inc.
Industry
Eligibility
18 Years to 40 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 3 Interventional Results available

Comparative Safety and Efficacy of Two Treatments in the Treatment of Acne Vulgaris

NCT02515305
View directory record Official record
Conditions
Acne
Interventions
Clindamycin and Benzoyl Peroxide Gel (combination), Clindamycin and Benzoyl Peroxide Gel (Reference) (combination), Placebo gel (combination)
Drug
Lead sponsor
Padagis LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
890 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2021 · Synced Oct 2, 2026, 4:50 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of the Use of Botox on Acne

NCT00765375
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Botulinum Neurotoxin Type A, Bacteriostatic saline
Drug
Lead sponsor
DeNova Research
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2018 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Impact of Clascoterone 1% Cream on Skin Barrier Properties in Acne Prone Patients

NCT06415292
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Winlevi (clascoterone) 1% cream
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study to Determine and Compare the Tolerance and Irritation Potential of Topical Acne Medications

NCT00964366
View directory record Official record
Conditions
Acne Vulgaris
Interventions
clindamycin and benzoyl peroxide, Dapsone gel
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years to 45 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Broomall, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of the Cutera Enlighten™ Laser With Micro-Lens Array (MLA) Handpiece Attachment

NCT03430921
View directory record Official record
Conditions
Scarring, Acne
Interventions
Enlighten™ Laser and a MLA Attachment
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Brisbane, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2023 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 4 Interventional Results available

Assessment of Subjects' Efficacy and Experiences Using Adapalene BPO Gel in the Treatment of Acne Vulgaris

NCT01209949
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Adapalene 0.1% and Benzoyl Peroxide 2.5% gel
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
16 Years to 25 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Carrollton, Texas
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety Study of Gevokizumab to Treat Moderate to Severe Acne Vulgaris

NCT01498874
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Placebo, gevokizumab
Drug
Lead sponsor
XOMA (US) LLC
Industry
Eligibility
17 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
19
States / cities
Hot Springs, Arkansas • Riverside, California • San Diego, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2014 · Synced Oct 2, 2026, 4:50 AM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris

NCT01501799
View directory record Official record
Conditions
Acne Vulgaris
Interventions
adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO, Placebo (Vehicle Gel)
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
12 Years to 40 Years
Enrollment
885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Fremont, California • Miami, Florida • Miramar, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Oct 2, 2026, 4:50 AM EDT